In contrast, publications reporting on the use of another mAb, AFS98, for M-CSFR blockade and ensuing TAM inhibition, documented inhibition of primary tumor growth in different mouse tumor models including the implanted AX osteosarcoma model (102) and later also in the EL4 transplanted lymphoma model, the PyMT transgenic breast carcinoma model and the MDA-MB231 breast cancer metastasis-induced osteolysis model (101). Here, CSF1R is linked to breast carcinoma.